Cargando…
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30–50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthroug...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573228/ https://www.ncbi.nlm.nih.gov/pubmed/26421294 http://dx.doi.org/10.1155/2015/595894 |